Compare CVGI & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVGI | IFRX |
|---|---|---|
| Founded | 2000 | 2007 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.5M | 60.6M |
| IPO Year | 2004 | 2017 |
| Metric | CVGI | IFRX |
|---|---|---|
| Price | $2.90 | $0.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | ★ 873.1K | 171.7K |
| Earning Date | 06-15-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 316.18 | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $755,231,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.47 | $1,054.36 |
| P/E Ratio | $58.25 | ★ N/A |
| Revenue Growth | ★ 14.06 | N/A |
| 52 Week Low | $0.81 | $0.71 |
| 52 Week High | $2.62 | $1.94 |
| Indicator | CVGI | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 78.78 | 52.69 |
| Support Level | $1.49 | $0.75 |
| Resistance Level | N/A | $1.16 |
| Average True Range (ATR) | 0.21 | 0.07 |
| MACD | 0.10 | 0.01 |
| Stochastic Oscillator | 100.00 | 50.85 |
Commercial Vehicle Group Inc is a provider of systems, assemblies, and components to the commercial vehicle market and the electric vehicle markets. It delivers solutions to complex design, engineering, and manufacturing problems while creating positive change for customers, industries, and communities. Its operating segments are Vehicle Solutions, Electrical Systems, and Aftermarket and Accessories. The company makes the majority of its revenue from Vehicle Solutions. The group generates revenue from its products including seating systems, plastic components, electrical wire harnesses, mirrors, wipers, and other accessories. Its geographic regions are North America, Europe and Asia-Pacific.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.